Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 25 2021 - 9:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2021
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in
its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This Report on Form 6-K (excluding Exhibit
99.1) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163
and 333-248479) and Form F-3 (File No. 333-229486, 333-228054 and 333-238731), to be a part thereof from the date on which this
report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On February 24, 2021,
Collplant Biotechnologies Ltd. (the “Company”) received a notice of termination from Lung Biotechnology PBC (“LB”),
a subsidiary of United Therapeutics Corporation, of the License, Development and Commercialization Agreement previously entered
into with LB, such termination to be effective March 26, 2021. On February 25, 2021, the Company issued a press release entitled
“Termination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants”. A copy of the press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD.
|
|
|
|
Date: February 25, 2021
|
By:
|
/s/ Eran Rotem
|
|
|
Name:
|
Eran Rotem
|
|
|
Title:
|
Deputy CEO and Chief Financial Officer
|
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024